Related Experiment Video

Updated: May 11, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Therapeutic vaccines and immunotherapy in castration-resistant prostate cancer: current progress and clinical

James L Gulley1, Ravi A Madan, Christopher R Heery

  • 1From the Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.

American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|May 30, 2013
PubMed

Insights

Prostate cancer immunotherapy shows promise with therapeutic vaccines like sipuleucel-T and PROSTVAC, offering improved survival and fewer side effects than chemotherapy. Immune checkpoint inhibitors are also under investigation.

Area of Science:

  • Oncology
  • Immunology
  • Clinical Trials

Background:

  • Immunotherapy is gaining traction for cancer treatment.
  • Prostate cancer patients are a promising group for immunotherapy.
  • Therapeutic cancer vaccines have shown improved survival rates and reduced side effects compared to chemotherapy.

Purpose of the Study:

  • To review recent clinical trial data on prostate cancer immunotherapy.
  • To discuss the implications of sipuleucel-T and PROSTVAC.
  • To highlight ongoing research with immune checkpoint inhibitors like ipilimumab.

Main Methods:

  • Review of clinical trial data for prostate cancer immunotherapy.
  • Focus on therapeutic cancer vaccines (sipuleucel-T, PROSTVAC).
  • Examination of immune checkpoint inhibitors (ipilimumab) in phase III trials.

Main Results:

  • Therapeutic vaccines demonstrate statistically significant improvements in overall survival.
  • Vaccines offer a better side effect profile than traditional chemotherapy.
  • Immune checkpoint inhibitors are being actively investigated in late-stage trials.

Conclusions:

  • Immunotherapy, particularly vaccines and checkpoint inhibitors, represents a significant advancement in prostate cancer treatment.
  • Further research is needed to address remaining questions and optimize clinical application.
  • These novel strategies offer hope for improved patient outcomes in prostate cancer.

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...